Annotation

Excerpt from the Dasatinib (Sprycel) EPAR:

SPRYCEL is indicated for the treatment of adult patients with:

• newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
• chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.
• Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

This information is highlighted in the following sections:

Therapeutic indications, package leaflet: information for the user.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Dasatinib EMA drug label.

*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.